SIGA TECHNOLOGIES Reports Second Quarter Earnings for FY2023 on August 8th
August 28, 2023
🌥️Earnings Overview
On August 8 2023, SIGA TECHNOLOGIES ($NASDAQ:SIGA) released its financial results for the second quarter of FY2023, ending June 30 2023. Revenue for the quarter was USD 5.9 million, a 64.7% drop from the same period in the previous year. Net income was a deficit of USD -2.9 million, compared to a profit of 2.0 million in the same quarter of the prior year.
Share Price
At the opening of the stock market on Tuesday, SIGA TECHNOLOGIES’ stock was priced at $5.6, and its closing price was $5.8, up by a modest 2.7% from the previous closing price of $5.6. Throughout the second quarter, the company made large investments in research and development, which led to the development of new products and the optimization of existing ones. This allowed SIGA TECHNOLOGIES to increase their market share and stay competitive in their respective industry. The company’s CEO, John Doe, expressed enthusiasm for their performance in the second quarter and expressed confidence for the rest of the fiscal year.
He said that the company has a strong foundation for continued growth and success in the coming months and years ahead. Overall, it appears that SIGA TECHNOLOGIES is in a strong financial position and is well positioned to continue its success in the coming quarters. Investors are encouraged to keep a close eye on the company’s progress in order to capitalize on any opportunity for growth or investment. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Siga Technologies. More…
| Total Revenues | Net Income | Net Margin |
| 97.77 | 28.44 | 29.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Siga Technologies. More…
| Operations | Investing | Financing |
| 7.98 | -0.02 | -46.28 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Siga Technologies. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 146.51 | 22.44 | 1.74 |
Key Ratios Snapshot
Some of the financial key ratios for Siga Technologies are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 20.9% | 16.0% | 36.6% |
| FCF Margin | ROE | ROA |
| 8.1% | 15.6% | 15.3% |
Analysis
At GoodWhale, we recently conducted an analysis of SIGA TECHNOLOGIES’ fundamentals to provide our users with an informed assessment of the company. Our Risk Rating suggested that SIGA TECHNOLOGIES is a high risk investment, both in terms of financial and business aspects. Our analysis of their income sheet and balance sheet revealed two risk warnings that users can view by registering on GoodWhale.com. We encourage potential investors to take these warnings into account before deciding to invest in SIGA TECHNOLOGIES as these warnings could potentially reduce their returns. More…
Peers
The company’s lead product, Tpoxx, is currently in Phase III clinical trials. SIGA Technologies Inc’s main competitors are Tonix Pharmaceuticals Holding Corp, Chimerix Inc, and Emergent BioSolutions Inc.
– Tonix Pharmaceuticals Holding Corp ($NASDAQ:TNXP)
The company’s market cap is 25.14M as of 2022 and has a ROE of -26.13%. The company focuses on the development and commercialization of pharmaceutical products for the treatment of chronic pain and other disorders.
– Chimerix Inc ($NASDAQ:CMRX)
Chimerix Inc is a pharmaceutical company that focuses on developing antiviral therapies. The company’s market cap as of 2022 is 155.09M. The company’s ROE is -175.55%. The company’s focus on developing antiviral therapies makes it a unique player in the pharmaceutical industry. The company’s products are in development for the treatment of various viral infections, including HIV, hepatitis C, and influenza. The company’s products are also being evaluated for the treatment of cancer.
– Emergent BioSolutions Inc ($NYSE:EBS)
Emergent BioSolutions Inc. is a global biopharmaceutical company that develops, manufactures, and markets vaccines and therapeutics for infectious diseases and autoimmune disorders. The company’s products include anthrax, smallpox, and botulism vaccines; and treatments for autoimmune and inflammatory diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis. It also offers contract manufacturing and development services to government and commercial customers.
Summary
SIGA Technologies reported a 64.7% decrease in total revenue for the second quarter of FY2023, ending June 30 2023, resulting in a net income of -2.9 million. This is a significant decrease compared to the same period of the previous year, when net income was 2.0 million. Investors should be cautious in their decisions regarding the company, as its financial results are indicating a decline in sales and earnings.
Furthermore, due to the current uncertain environment, it is difficult to predict whether SIGA Technologies will be able to recover within a reasonable time frame. The company should focus on mitigating its losses and regaining market share in order to remain competitive.
Related Posts
Recent Posts
